Wednesday, March 11, 2026 3/11/2026

Registering Cancer Recurrences in the Georgia Cancer Registry

Award Number: R01CA234538
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 02/15/2019
PERIOD OF PERFORMANCE END DATE: 07/31/2025

Group Awards By:

View Award Description

Registering Cancer Recurrences in the Georgia Cancer Registry - There are 15 million US cancer survivors, most diagnosed with early-stage disease, so at risk for a cancer recurrence. There is no population-based information about the risk of cancer recurrence. For decades, mortality has been the only outcome available to monitor progress in cancer care. As cancer care has improved, however, the correspondence between recurrence and mortality has diminished. A recent commentary in the Journal of the National Cancer Institute emphasized that the lack of surveillance data on recurrence is a barrier to comparative effectiveness research in the realm of cancer care and to research on cancer quality-of-care. In the clinical setting, the lack of even basic recurrence risk data by cancer type and stage is a barrier to informed patient-physician decision-making and risk stratification. A high-quality registry of cancer recurrences would fill these gaps, open new avenues for cancer research, and enable improvements in clinical care tied directly to the most salient and immediate outcome for all early-stage cancer patients. Georgia provides an ideal setting for the first-ever registry of cancer recurrences. The population of about 10 million is diverse with respect to all major demographic characteristics. The large population ensures that adequate data on recurrences will accumulate rapidly. The diverse population assures that heterogeneity of recurrence risk by demographic characteristics will be adequately characterized. The Georgia Cancer Registry has been a long-term member of the National Cancer Institute’s Surveillance Epidemiology and End Results program, the National Program for Cancer Registries established by the Centers for Disease Control and Prevention, and the North American Association of Central Cancer Registries. Thus, Georgia has the right population and the Georgia Cancer Registry has the right infrastructure to accomplish the following two aims: Aim #1: Use six data streams to signal potential recurrences occuring among Georgia cancer survivors diagnosed with one of four cancer types (breast, prostate, colorectal, or lymphoma), review medical records to validate true recurrences, and implement constant learning processes to improve accuracy, efficiency, and sustainability of the registration process. Aim #2: For these four cancer types, which represent 43% of incident cases and 58% of prevalent survivors in the US, generate the first-ever descriptive data on the risks and rates of recurrence over ten years of follow-up and evaluate how these vary by demographic characteristics. By achieving these aims, we will fill an important gap in the knowledge base regarding cancer outcomes and provide a foundation for innovative research on patterns and predictors of recurrence. The recurrence data will be available to other researchers through existing mechanisms, so resource sharing will be enabled from the outset. Furthermore, as the infrastructure solidifies and the methods are optimized, the recurrence registration protocols will be transportable to cancer registries with similar infrastructure and legal authority .


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = -$1 )
2026	2024	EMORY UNIVERSITY	201 DOWMAN DR NE	ATLANTA	GA	30322	DEKALB	USA	Cancer Cause and Prevention Research	000	6	12/8/2025	NON-COMPETING CONTINUATION	-$1
														Subtotal = -$1

Issue Date FY: 2024 ( Subtotal = $26,979 )
2024	2024	EMORY UNIVERSITY	201 DOWMAN DR NE	ATLANTA	GA	30322	DEKALB	USA	Cancer Cause and Prevention Research	001	6	8/21/2024	NON-COMPETING CONTINUATION	$26,979
2024	2023	EMORY UNIVERSITY	201 DOWMAN DR	ATLANTA	GA	30322	DEKALB	USA	Cancer Cause and Prevention Research	000	5	3/1/2024	NON-COMPETING CONTINUATION	$0
														Subtotal = $26,979

Issue Date FY: 2023 ( Subtotal = $635,548 )
2023	2023	EMORY UNIVERSITY	201 DOWMAN DR	ATLANTA	GA	30322	DEKALB	USA	Cancer Cause and Prevention Research	000	5	2/23/2023	NON-COMPETING CONTINUATION	$635,548
														Subtotal = $635,548

Issue Date FY: 2022 ( Subtotal = $631,169 )
2022	2022	EMORY UNIVERSITY	201 DOWMAN DR	ATLANTA	GA	30322	DEKALB	USA	Cancer Cause and Prevention Research	000	4	1/26/2022	NON-COMPETING CONTINUATION	$579,643
2022	2022	EMORY UNIVERSITY	201 DOWMAN DR	ATLANTA	GA	30322	DEKALB	USA	Cancer Cause and Prevention Research	001	4	4/26/2022	NON-COMPETING CONTINUATION	$51,526
														Subtotal = $631,169

Issue Date FY: 2021 ( Subtotal = $639,928 )
2021	2021	EMORY UNIVERSITY	201 DOWMAN DR	ATLANTA	GA	30322	DEKALB	USA	Cancer Cause and Prevention Research	000	3	1/18/2021	NON-COMPETING CONTINUATION	$639,928
														Subtotal = $639,928

Issue Date FY: 2020 ( Subtotal = $268,597 )
2020	2020	EMORY UNIVERSITY	201 DOWMAN DR	ATLANTA	GA	30322	DEKALB	USA	Cancer Cause and Prevention Research	000	2	4/3/2020	NON-COMPETING CONTINUATION	$268,597
														Subtotal = $268,597

Issue Date FY: 2019 ( Subtotal = $615,744 )
2019	2019	EMORY UNIVERSITY	1599 CLIFTON RD.	ATLANTA	GA	30322	DEKALB	USA	Cancer Cause and Prevention Research	000	1	2/13/2019	NEW	$615,744
														Subtotal = $615,744

Grand Total All Awards = $2,817,964

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Registering Cancer Recurrences in the Georgia Cancer Registry

Award Number: R01CA234538

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 02/15/2019

PERIOD OF PERFORMANCE END DATE: 07/31/2025

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer